Company news

Geron Corporation news in 2024

Geron Corporation's news releases, calls and decks from 2024, newest first.

View company

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

December 12, 2024

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

December 9, 2024

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

December 9, 2024

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

Geron to Participate in the Stifel 2024 Healthcare Conference

November 10, 2024

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

November 10, 2024

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 6, 2024

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

November 6, 2024

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

November 4, 2024

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

October 14, 2024

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

September 8, 2024

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

August 7, 2024

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

July 25, 2024

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

July 22, 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

July 17, 2024

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

June 5, 2024

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

April 24, 2024

Geron to Participate at Upcoming Investor Conferences in April

April 2, 2024

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

March 18, 2024

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

March 13, 2024

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 13, 2024

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

January 11, 2024

Calls in 2024

Decks in 2024